Toll‐like receptors 7, 8, and 9: linking innate immunity to autoimmunity
暂无分享,去创建一个
[1] L. Audoly,et al. Corrigendum: Toll-like receptor 9—dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE , 2007, Nature Immunology.
[2] H. Anders,et al. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. , 2007, Journal of the American Society of Nephrology : JASN.
[3] S. Akira,et al. Murine Dendritic Cell Type I IFN Production Induced by Human IgG-RNA Immune Complexes Is IFN Regulatory Factor (IRF)5 and IRF7 Dependent and Is Required for IL-6 Production1 , 2007, The Journal of Immunology.
[4] S. Vogel,et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming , 2007, Proceedings of the National Academy of Sciences.
[5] B. Beutler,et al. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity , 2007, Nature Medicine.
[6] T. Mayadas,et al. Functions of TNF and its receptors in renal disease: distinct roles in inflammatory tissue injury and immune regulation. , 2007, Seminars in nephrology.
[7] V. Hornung,et al. Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response. , 2007, Blood.
[8] L. Audoly,et al. Regulation of TLR9 dependent DNA Immune complex mediated cell activation by High Mobility Group Box Protein 1 (HMGB1) and Receptor for Advanced Glycation End products (RAGE) (128.35) , 2007, Journal of Immunology.
[9] A. Iwasaki,et al. In Brief , 2007, Nature Reviews Immunology.
[10] D. Busch,et al. Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivo. , 2007, International immunology.
[11] S. Boulo,et al. Nuclear traffic of influenza virus proteins and ribonucleoprotein complexes. , 2007, Virus research.
[12] Shizuo Akira,et al. Antiviral signaling through pattern recognition receptors. , 2006, Journal of biochemistry.
[13] Jianyong Wang,et al. The Functional Effects of Physical Interactions among Toll-like Receptors 7, 8, and 9* , 2006, Journal of Biological Chemistry.
[14] H. Anders,et al. Ligands to nucleic acid-specific toll-like receptors and the onset of lupus nephritis. , 2006, Journal of the American Society of Nephrology : JASN.
[15] S. Akira,et al. Nucleic acid agonists for Toll‐like receptor 7 are defined by the presence of uridine ribonucleotides , 2006, European journal of immunology.
[16] J. Battiste,et al. Oligodeoxynucleotides Differentially Modulate Activation of TLR7 and TLR8 by Imidazoquinolines , 2006, The Journal of Immunology.
[17] Yu-Tseung Liu,et al. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells , 2006, Nature Cell Biology.
[18] John P. Vasilakos,et al. Cutting Edge: Activation of Murine TLR8 by a Combination of Imidazoquinoline Immune Response Modifiers and PolyT Oligodeoxynucleotides , 2006, The Journal of Immunology.
[19] M. Madaio,et al. Modulation of Autoimmunity by TLR9 in the Chronic Graft-vs-Host Model of Systemic Lupus Erythematosus1 , 2006, The Journal of Immunology.
[20] Douglas T. Golenbock,et al. Flavivirus Activation of Plasmacytoid Dendritic Cells Delineates Key Elements of TLR7 Signaling beyond Endosomal Recognition1 , 2006, The Journal of Immunology.
[21] Gunther Hartmann,et al. 5'-Triphosphate RNA Is the Ligand for RIG-I , 2006, Science.
[22] A. Pichlmair,et al. RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 5'-Phosphates , 2006, Science.
[23] C. Tsatsanis,et al. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. , 2006, Arthritis and rheumatism.
[24] A. Marshak‐Rothstein. Toll-like receptors in systemic autoimmune disease , 2006, Nature Reviews Immunology.
[25] K. Ishii,et al. Innate immune recognition of, and regulation by, DNA. , 2006, Trends in immunology.
[26] D. Jarrossay,et al. Distinct expression pattern of IFN-α and TNF-α in juvenile idiopathic arthritis synovial tissue , 2006 .
[27] R. Coffman,et al. Immunotherapy With a Ragweed-Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis , 2007, Pediatrics.
[28] R. Lafyatis,et al. Antimalarial agents: closing the gate on Toll-like receptors? , 2006, Arthritis and rheumatism.
[29] H. Anders,et al. Microbial nucleic acids pay a Toll in kidney disease. , 2006, American journal of physiology. Renal physiology.
[30] T. Ghosh,et al. Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. , 2006, Cellular immunology.
[31] J. Shupe,et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. , 2006, Immunity.
[32] S. Akira,et al. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. , 2006, The Journal of clinical investigation.
[33] H. Hackstein,et al. TLR7 Ligands Induce Higher IFN-α Production in Females1 , 2006, The Journal of Immunology.
[34] T. Winkler,et al. Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE. , 2006, International immunology.
[35] C. McCaig,et al. Expression of the human PAC1 receptor leads to dose-dependent hydrocephalus-related abnormalities in mice. , 2006, The Journal of clinical investigation.
[36] G. Cheng,et al. TLR Activation of Langerhans Cell-Like Dendritic Cells Triggers an Antiviral Immune Response1 , 2006, The Journal of Immunology.
[37] Marion Jurk,et al. Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T‐rich phosphorothiate oligodeoxynucleotides , 2006, European journal of immunology.
[38] Quanzhen Li,et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[39] A. Satterthwaite,et al. Autoreactive B Cell Responses to RNA-Related Antigens Due to TLR7 Gene Duplication , 2006, Science.
[40] A. Krieg,et al. Therapeutic potential of Toll-like receptor 9 activation , 2006, Nature Reviews Drug Discovery.
[41] H. Rammensee,et al. Genetic Vaccines and Therapy , 2006 .
[42] M. Sioud. Single‐stranded small interfering RNA are more immunostimulatory than their double‐stranded counterparts: A central role for 2′‐hydroxyl uridines in immune responses , 2006, European journal of immunology.
[43] R. Ashman,et al. Extended sequence preferences for oligodeoxyribonucleotide activity , 2006, Immunology.
[44] C. Lucchesi,et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[45] B. Becher,et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. , 2006, The Journal of clinical investigation.
[46] J. Langley,et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. , 2006, Vaccine.
[47] J. Vollmer. TLR9 in Health and Disease , 2006, International reviews of immunology.
[48] D. Busch,et al. Systemic application of CpG‐rich DNA suppresses adaptive T cell immunity via induction of IDO , 2006, European journal of immunology.
[49] S. Akira,et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8 , 2005, The Journal of experimental medicine.
[50] H. S. Warren,et al. Toll-like receptors. , 2005, Critical care medicine.
[51] S. Su,et al. Essential Role of the MyD88 Pathway, but Nonessential Roles of TLRs 2, 4, and 9, in the Adjuvant Effect Promoting Th1-Mediated Autoimmunity , 2005, The Journal of Immunology.
[52] S. Akira,et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement , 2005, The Journal of experimental medicine.
[53] A. DeFranco,et al. TLR3 and TLR7 Are Targeted to the Same Intracellular Compartments by Distinct Regulatory Elements*♦ , 2005, Journal of Biological Chemistry.
[54] B. Baban,et al. Cutting Edge: CpG Oligonucleotides Induce Splenic CD19+ Dendritic Cells to Acquire Potent Indoleamine 2,3-Dioxygenase-Dependent T Cell Regulatory Functions via IFN Type 1 Signaling1 , 2005, The Journal of Immunology.
[55] S. Akira,et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus , 2005, The Journal of experimental medicine.
[56] F. Weber,et al. Activation of Innate Defense against a Paramyxovirus Is Mediated by RIG-I and TLR7 and TLR8 in a Cell-Type-Specific Manner , 2005, Journal of Virology.
[57] C. Hofmann,et al. CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. , 2005, Gastroenterology.
[58] Houping Ni,et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. , 2005, Immunity.
[59] L. Joosten,et al. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. , 2005, Arthritis and rheumatism.
[60] S. Akira,et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus , 2005, The Journal of experimental medicine.
[61] M. Sioud. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. , 2005 .
[62] W. Falk,et al. In vivo CpG DNA/toll-like receptor 9 interaction induces regulatory properties in CD4+CD62L+ T cells which prevent intestinal inflammation in the SCID transfer model of colitis , 2005, Gut.
[63] M. Kretzler,et al. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. , 2005, Journal of the American Society of Nephrology : JASN.
[64] M. Peterson,et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. , 2005, Arthritis and rheumatism.
[65] J. Lesher,et al. Tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia. , 2005, Journal of the American Academy of Dermatology.
[66] D. Klinman,et al. Suppressive Oligodeoxynucleotides Protect Mice from Lethal Endotoxic Shock1 , 2005, The Journal of Immunology.
[67] A. Judge,et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.
[68] L. Eckmann,et al. Amendment history : Corrigendum ( April 2005 ) Toll-like receptor 9 – induced type I IFN protects mice from experimental colitis , 2018 .
[69] D. Speiser,et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. , 2005, The Journal of clinical investigation.
[70] S. Akira,et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 , 2005, Nature Medicine.
[71] K. Ishii,et al. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. , 2005, Arthritis and rheumatism.
[72] J. Bach. A Toll-like trigger for autoimmune disease , 2005, Nature Medicine.
[73] M. Tomai,et al. Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8 , 2005, The Journal of Immunology.
[74] S. Akira,et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease , 2005, Nature Medicine.
[75] J. Friedberg,et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. , 2005, Blood.
[76] P. Pietschmann,et al. Rheumatoid arthritis synovium contains plasmacytoid dendritic cells , 2005, Arthritis research & therapy.
[77] P. Gregersen,et al. The emerging role of interferon in human systemic lupus erythematosus. , 2004, Current opinion in immunology.
[78] S. Agrawal,et al. Antisense and siRNA as agonists of Toll-like receptors , 2004, Nature Biotechnology.
[79] A. Krieg,et al. Induction of Systemic TH1-Like Innate Immunity in Normal Volunteers Following Subcutaneous but Not Intravenous Administration of CPG 7909, a Synthetic B-Class CpG Oligodeoxynucleotide TLR9 Agonist , 2004, Journal of immunotherapy.
[80] H. Gollnick,et al. Androgen receptor status in lesional and normal skin of patients with rosacea , 2004, Journal of the European Academy of Dermatology and Venereology : JEADV.
[81] C. Cooper,et al. CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study , 2004, Journal of Clinical Immunology.
[82] Angela Panoskaltsis-Mortari,et al. Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulatory T Cells1 , 2004, The Journal of Immunology.
[83] J. Metzger,et al. Toll‐like receptor 9 binds single‐stranded CpG‐DNA in a sequence‐ and pH‐dependent manner , 2004, European journal of immunology.
[84] S. Young,et al. U1 RNA induces innate immunity signaling. , 2004, Arthritis and rheumatism.
[85] Y. Li,et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. , 2004, Vaccine.
[86] D. Pisetsky,et al. Release of DNA from Dead and Dying Lymphocyte and Monocyte Cell Lines In Vitro , 2004, Scandinavian journal of immunology.
[87] J. LaManna,et al. The Third Signal in T Cell-Mediated Autoimmune Disease?1 , 2004, The Journal of Immunology.
[88] L. Rönnblom,et al. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. , 2004, Arthritis and rheumatism.
[89] A. DeFranco,et al. Ligand-regulated Chimeric Receptor Approach Reveals Distinctive Subcellular Localization and Signaling Properties of the Toll-like Receptors* , 2004, Journal of Biological Chemistry.
[90] Akiko Iwasaki,et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[91] S. Akira,et al. Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8 , 2004, Science.
[92] Shizuo Akira,et al. Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.
[93] C. Hughes,et al. Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.
[94] John J Rossi,et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase , 2004, Nature Biotechnology.
[95] L. Wen,et al. The Effect of Innate Immunity on Autoimmune Diabetes and the Expression of Toll-Like Receptors on Pancreatic Islets1 , 2004, The Journal of Immunology.
[96] H. Rammensee,et al. Immunostimulating capacities of stabilized RNA molecules , 2004, European journal of immunology.
[97] S. Akira,et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration , 2004, Nature Medicine.
[98] R. DeMatteo,et al. Liver Dendritic Cells Are Less Immunogenic Than Spleen Dendritic Cells because of Differences in Subtype Composition1 , 2004, The Journal of Immunology.
[99] Hongsheng Wang,et al. Impaired Clearance of Apoptotic Cells Induces the Activation of Autoreactive Anti-Sm Marginal Zone and B-1 B Cells 1 , 2004, The Journal of Immunology.
[100] R. Coffman,et al. IMMUNOBIOLOGY: IL-10 Regulates Plasmacytoid Dendritic Cell Response to CpG Containing ImmunoStimulatory Sequences , 2003 .
[101] T. Utsugi,et al. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. , 2003, Immunity.
[102] K. Lamberth,et al. Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross‐reactive, natural HBsAg variants , 2003, European journal of immunology.
[103] M. Shlomchik,et al. Activation of autoreactive B cells by CpG dsDNA. , 2003, Immunity.
[104] Lukas Hunziker,et al. Dendritic cell–induced autoimmune heart failure requires cooperation between adaptive and innate immunity , 2003, Nature Medicine.
[105] S. Akira,et al. The Toll‐like receptor 7 (TLR7)‐specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily , 2003, European journal of immunology.
[106] W. Falk,et al. Contrasting activity of cytosin–guanosin dinucleotide oligonucleotides in mice with experimental colitis , 2003, Clinical and experimental immunology.
[107] K. Hasegawa,et al. Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB ×NZWF1 mice , 2003, Lupus.
[108] M. Crow. Interferon-α: A new target for therapy in systemic lupus erythematosus? , 2003 .
[109] G. Stark,et al. SIGIRR, a negative regulator of Toll-like receptor–interleukin 1 receptor signaling , 2003, Nature Immunology.
[110] R. Tisch,et al. More Stringent Conditions of Plasmid DNA Vaccination Are Required to Protect Grafted Versus Endogenous Islets in Nonobese Diabetic Mice 1 , 2003, The Journal of Immunology.
[111] S. Halperin,et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. , 2003, Vaccine.
[112] C. Goodnow,et al. Resistance to CpG DNA–induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling , 2003, Nature Immunology.
[113] K. Ishii,et al. Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. , 2003, Arthritis and rheumatism.
[114] A. Krieg,et al. CpG-A-Induced Monocyte IFN-γ-Inducible Protein-10 Production Is Regulated by Plasmacytoid Dendritic Cell-Derived IFN-α1 , 2003, The Journal of Immunology.
[115] J. Hardin. Directing Autoimmunity to Nucleoprotein Particles , 2003, The Journal of experimental medicine.
[116] R. Gay,et al. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. , 2003, Arthritis and rheumatism.
[117] G. Karypis,et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[118] C. Cohen,et al. Bacterial CpG-DNA aggravates immune complex glomerulonephritis: role of TLR9-mediated expression of chemokines and chemokine receptors. , 2003, Journal of the American Society of Nephrology : JASN.
[119] Ruslan Medzhitov,et al. Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.
[120] Jae-Geun Yoon,et al. CpG DNA Induces Self and Cross-Hyporesponsiveness of RAW264.7 Cells in Response to CpG DNA and Lipopolysaccharide: Alterations in IL-1 Receptor-Associated Kinase Expression1 , 2003, The Journal of Immunology.
[121] G. Trinchieri,et al. Flexibility of Mouse Classical and Plasmacytoid-derived Dendritic Cells in Directing T Helper Type 1 and 2 Cell Development , 2003, The Journal of experimental medicine.
[122] A. Krieg. CpG DNA: Trigger of Sepsis, Mediator of Protection, or Both? , 2003, Scandinavian journal of infectious diseases.
[123] T. Bieber,et al. Successful Treatment of Chronic Discoid Lupus erythematosus of the Scalp with Imiquimod , 2002, Dermatology.
[124] T. Nichterlein,et al. CpG‐ODN‐induced inflammation is sufficient to cause T‐cell‐mediated autoaggression against hepatocytes , 2002, European journal of immunology.
[125] I. Cohen,et al. DNA Vaccination with Heat Shock Protein 60 Inhibits Cyclophosphamide-Accelerated Diabetes1 , 2002, The Journal of Immunology.
[126] K. Ishii,et al. Effect of Suppressive DNA on CpG-Induced Immune Activation1 , 2002, The Journal of Immunology.
[127] K. Hasegawa,et al. CpG oligodeoxynucleotides accelerate reovirus type 2‐triggered insulitis in DBA/1 suckling mice , 2002, International journal of experimental pathology.
[128] B. Segal,et al. Activation of APCs Through CD40 or Toll-Like Receptor 9 Overcomes Tolerance and Precipitates Autoimmune Disease1 , 2002, The Journal of Immunology.
[129] Lin Chen,et al. CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease , 2002, Neuroscience Letters.
[130] J. Charles Jennette,et al. Delayed Apoptotic Cell Clearance and Lupus-like Autoimmunity in Mice Lacking the c-mer Membrane Tyrosine Kinase , 2002, The Journal of experimental medicine.
[131] J. Schölmerich,et al. CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium‐treated mice , 2002, European journal of immunology.
[132] S. Akira,et al. Interferon-α and Interleukin-12 Are Induced Differentially by Toll-like Receptor 7 Ligands in Human Blood Dendritic Cell Subsets , 2002, The Journal of experimental medicine.
[133] H. Wagner,et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848 , 2002, Nature Immunology.
[134] A. Gillum,et al. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. , 2002, Antisense & nucleic acid drug development.
[135] K. Heeg,et al. Immunostimulatory CpG-DNA Activates Murine Microglia1 , 2002, The Journal of Immunology.
[136] Jae-Geun Yoon,et al. Role of Mitogen-Activated Protein Kinases in CpG DNA-Mediated IL-10 and IL-12 Production: Central Role of Extracellular Signal-Regulated Kinase in the Negative Feedback Loop of the CpG DNA-Mediated Th1 Response1 , 2002, The Journal of Immunology.
[137] Jongdae Lee,et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. , 2002, Gastroenterology.
[138] A. Krieg. A role for Toll in autoimmunity , 2002, Nature Immunology.
[139] T. Giese,et al. Quantitative Expression of Toll-Like Receptor 1–10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides1 , 2002, The Journal of Immunology.
[140] M. Shlomchik,et al. Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors , 2002, Nature.
[141] P. Godowski,et al. Tissue Expression of Human Toll-Like Receptors and Differential Regulation of Toll-Like Receptor mRNAs in Leukocytes in Response to Microbes, Their Products, and Cytokines , 2002, The Journal of Immunology.
[142] Michel C. Nussenzweig,et al. Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[143] G. Firestein,et al. References Subscriptions Permissions Email Alerts Immunostimulatory DNA Sequences Influence the Course of Adjuvant Arthritis , 2013 .
[144] L. Rönnblom,et al. A Pivotal Role for the Natural Interferon α–producing Cells (Plasmacytoid Dendritic Cells) in the Pathogenesis of Lupus , 2001, The Journal of experimental medicine.
[145] L. Rönnblom,et al. Importance of CpG Dinucleotides in Activation of Natural IFN‐α‐Producing Cells by a Lupus‐Related Oligodeoxynucleotide , 2001, Scandinavian journal of immunology.
[146] Virginia Pascual,et al. Induction of Dendritic Cell Differentiation by IFN-α in Systemic Lupus Erythematosus , 2001, Science.
[147] A. Tarkowski,et al. Intracisternally Localized Bacterial DNA Containing CpG Motifs Induces Meningitis1 , 2001, The Journal of Immunology.
[148] I. Julkunen,et al. IFNs activate toll-like receptor gene expression in viral infections , 2001, Genes and Immunity.
[149] N. Kadowaki,et al. Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial Antigens , 2001, The Journal of experimental medicine.
[150] C. Whitacre. Sex differences in autoimmune disease , 2001, Nature Immunology.
[151] M. V. von Herrath,et al. Plasmid Vaccination with Insulin B Chain Prevents Autoimmune Diabetes in Nonobese Diabetic Mice1 , 2001, The Journal of Immunology.
[152] T. Giese,et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. , 2001, European journal of immunology.
[153] J. Portanova,et al. CpG DNA induces cyclooxygenase-2 expression and prostaglandin production. , 2001, International immunology.
[154] T. Horiuchi,et al. Mutation of DNASE1 in people with systemic lupus erythematosus , 2001, Nature Genetics.
[155] A. Krieg,et al. CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. , 2001, Antisense & nucleic acid drug development.
[156] S. Akira,et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[157] P. Payette,et al. CpG Oligodeoxynucleotides with Hepatitis B Surface Antigen (HBsAg) for Vaccination in HBsAg-Transgenic Mice , 2001, Journal of Virology.
[158] V. Hornung,et al. Identification of CpG oligonucleotide sequences with high induction of IFN‐α/β in plasmacytoid dendritic cells , 2001 .
[159] K. Heeg,et al. Suppressors of Cytokine Signaling (SOCS)-1 and SOCS-3 Are Induced by CpG-DNA and Modulate Cytokine Responses in APCs1 , 2001, The Journal of Immunology.
[160] R. Scott,et al. Phagocytosis and clearance of apoptotic cells is mediated by MER , 2001, Nature.
[161] J. Ellwart,et al. Bacterial CpG-DNA Triggers Activation and Maturation of Human CD11c−, CD123+ Dendritic Cells1 , 2001, The Journal of Immunology.
[162] N. Kadowaki,et al. Distinct CpG DNA and Polyinosinic-Polycytidylic Acid Double-Stranded RNA, Respectively, Stimulate CD11c− Type 2 Dendritic Cell Precursors and CD11c+ Dendritic Cells to Produce Type I IFN1 , 2001, The Journal of Immunology.
[163] J. Schwab,et al. Transient in vivo activation of rat brain macrophages/microglial cells and astrocytes by immunostimulatory multiple CpG oligonucleotides , 2001, Journal of Neuroimmunology.
[164] S. Akira,et al. A Toll-like receptor recognizes bacterial DNA , 2000, Nature.
[165] Asaf Rotem,et al. Vaccination with Empty Plasmid DNA or CpG Oligonucleotide Inhibits Diabetes in Nonobese Diabetic Mice: Modulation of Spontaneous 60-kDa Heat Shock Protein Autoimmunity1 , 2000, The Journal of Immunology.
[166] R. Kasukawa,et al. Unmethylated oligo-DNA containing CpG motifs aggravates collagen-induced arthritis in mice. , 2000, Arthritis and rheumatism.
[167] A. Tarkowski,et al. The major role of macrophages and their product tumor necrosis factor alpha in the induction of arthritis triggered by bacterial DNA containing CpG motifs. , 2000, Arthritis and rheumatism.
[168] L. Rönnblom,et al. The Combination of Apoptotic U937 Cells and Lupus IgG Is a Potent IFN-α Inducer3 , 2000, The Journal of Immunology.
[169] D. Isenberg,et al. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. , 2000, Arthritis and rheumatism.
[170] John T. Chang,et al. CpG Oligonucleotides Are Potent Adjuvants for the Activation of Autoreactive Encephalitogenic T Cells In Vivo , 2000, The Journal of Immunology.
[171] T. Möröy,et al. Features of systemic lupus erythematosus in Dnase1-deficient mice , 2000, Nature Genetics.
[172] K. Mokhtari,et al. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[173] V. Kouskoff,et al. T cell-independent rescue of B lymphocytes from peripheral immune tolerance. , 2000, Science.
[174] A. Krieg. Minding the Cs and Gs. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[175] A. Tarkowski,et al. The features of arthritis induced by CpG motifs in bacterial DNA. , 2000, Arthritis and rheumatism.
[176] R. Purcell,et al. Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo1 , 2000, The Journal of Immunology.
[177] L. Rönnblom,et al. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. , 1999, Journal of immunology.
[178] Lin Chen,et al. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. , 1999, Cancer research.
[179] G. Hartmann,et al. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[180] M. V. von Herrath,et al. DNA immunization to prevent autoimmune diabetes. , 1999, The Journal of clinical investigation.
[181] L. Strekowski,,et al. Structure-activity relationship analysis of substituted 4-quinolinamines, antagonists of immunostimulatory CpG-oligodeoxynucleotides. , 1999, Bioorganic & medicinal chemistry letters.
[182] Andrej Tarkowski,et al. Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis , 1999, Nature Medicine.
[183] P. Butler,et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity , 1999, Nature Medicine.
[184] J. Penninger,et al. Chlamydia infections and heart disease linked through antigenic mimicry. , 1999, Science.
[185] L. Hültner,et al. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. , 1999, Journal of immunology.
[186] T. Yamamoto,et al. How BCG led to the discovery of immunostimulatory DNA. , 1999, Japanese journal of infectious diseases.
[187] L. Steinman,et al. Non-coding plasmid DNA induces IFN-γ in vivo and suppresses autoimmune encephalomyelitis , 1999 .
[188] R. Kasukawa,et al. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. , 1999, The Journal of rheumatology.
[189] A. Levin,et al. Correlation of Toxicity and Pharmacokinetic Properties of a Phosphorothioate Oligonucleotide Designed to Inhibit ICAM-1 , 1999, Toxicologic pathology.
[190] K. Conzelmann. Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes. , 1998, Annual review of genetics.
[191] M. Hadchouel,et al. Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-gamma-secreting T cells after DNA-based immunization. , 1998, Journal of immunology.
[192] H. Mischak,et al. CpG‐DNA‐specific activation of antigen‐presenting cells requires stress kinase activity and is preceded by non‐specific endocytosis and endosomal maturation , 1998, The EMBO journal.
[193] A. Krieg,et al. Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides. , 1998, Journal of immunology.
[194] D. Pisetsky,et al. Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice. , 1998, Journal of immunology.
[195] T. Wu,et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[196] R. Voll,et al. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. , 1998, Arthritis and rheumatism.
[197] A. Krieg,et al. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. , 1998, Journal of immunology.
[198] Pier Paolo Pandolfi,et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies , 1998, Nature Genetics.
[199] L. Manzel,et al. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. , 1998, Journal of immunology.
[200] J. Piette,et al. Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. , 1997, Arthritis and rheumatism.
[201] S. Agrawal,et al. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. , 1997, Antisense & nucleic acid drug development.
[202] E. Shevach,et al. Microbial products induce autoimmune disease by an IL-12-dependent pathway. , 1997, Journal of immunology.
[203] S L Hoffman,et al. Do DNA vaccines induce autoimmune disease? , 1997, Human gene therapy.
[204] D. Klinman,et al. Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. , 1996, Journal of immunology.
[205] H. Davis,et al. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[206] D. Pisetsky,et al. Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA , 1996, The Journal of experimental medicine.
[207] G. Bishop,et al. CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.
[208] D. Pisetsky,et al. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. , 1991, Journal of immunology.
[209] H. Pircher,et al. Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic mice , 1991, Cell.
[210] C. Steinman,et al. Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. , 1990, The Journal of clinical investigation.
[211] D. Jarrossay,et al. Distinct expression pattern of IFN-alpha and TNF-alpha in juvenile idiopathic arthritis synovial tissue. , 2007, Rheumatology.
[212] R. Medzhitov,et al. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA , 2006, Nature Immunology.
[213] S. Peng,et al. Toll-like receptor 9 signaling protects against murine lupus. , 2006, Arthritis and rheumatism.
[214] L. Capelle,et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. , 2006, Neuro-oncology.
[215] H. Hackstein,et al. TLR7 ligands induce higher IFN-alpha production in females. , 2006, Journal of immunology.
[216] M. de Bandt. Lessons for lupus from tumour necrosis factor blockade. , 2006, Lupus.
[217] R. Ashman,et al. TLR-9 Activation of Marginal Zone B Cells in Lupus Mice Regulates Immunity Through Increased IL-10 Production , 2005, Journal of Clinical Immunology.
[218] N. Demaurex,et al. Endosome-to-cytosol transport of viral nucleocapsids , 2005, Nature Cell Biology.
[219] K. Elkon,et al. Autoantibodies make a U-turn: the toll hypothesis for autoantibody specificity , 2005 .
[220] L. Klareskog,et al. Oligodeoxynucleotides containing CpG motifs can induce T cell-dependent arthritis in rats. , 2004, Arthritis and rheumatism.
[221] J. Delattre,et al. CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma. , 2003, Frontiers in bioscience : a journal and virtual library.
[222] M. Crow. Interferon-alpha: a new target for therapy in systemic lupus erythematosus? , 2003, Arthritis and rheumatism.
[223] A. Krieg,et al. CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. , 2003, Journal of immunology.
[224] A. Krieg,et al. CpG motifs in bacterial DNA and their immune effects. , 2002, Annual review of immunology.
[225] R. Steinman. Inaugural Article : avoiding horror autotoxicus. The importance of dendritic cells in peripheral T cell tolerance , 2002 .
[226] V. Hornung,et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. , 2001, European journal of immunology.
[227] V. Pascual,et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. , 2001, Science.
[228] U. Båve,et al. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer. , 2000, Journal of immunology.
[229] A. Krieg,et al. Immune Effects of Bacterial DNA and Their Possible Role in the Pathogenesis of Lupus , 1999 .
[230] A. Krieg. Direct Immunologic activities of CpG DNA and implications for gene therapy , 1999, The journal of gene medicine.